四价登革热疫苗效力随机对照试验在亚洲和拉丁美洲的四年安全性随访
本文描述了三项比较四价登革热疫苗与安慰剂的随机临床试验中,从首剂后至第4年(第1至4年)经病毒学确诊登革热(VCD)住院和临床重症住院VCD的风险。结果显示,总体接种组住院VCD风险低于安慰剂组(RR=0.511,95%CI 0.42-0.62),≥9岁儿童接种组风险更低(RR=0.324,95%CI 0.24-0.43);<9岁儿童总体RR=0.786(95%CI 0.60-1.03),其中2-5岁儿童在第3年住院VCD病例多于对照组。结论认为≥9岁人群至第4年总体获益-风险仍为正向,但第3、4年保护效果低于第1、2年。
要点
- 总体接种组住院VCD风险低于安慰剂组(RR=0.511,95%CI 0.42-0.62)。
- ≥9岁儿童接种组住院VCD风险显著低于安慰剂组(RR=0.324,95%CI 0.24-0.43)。
- <9岁儿童总体RR=0.786(95%CI 0.60-1.03),2-5岁儿童第3年住院VCD病例多于对照组。
核心结论
- ≥9岁人群至第4年总体获益-风险仍为正向,但第3、4年保护效果低于第1、2年。
研究设计与样本
- 三项比较四价登革热疫苗与安慰剂的随机临床试验,接种组n=22 603,安慰剂组n=11 301,随访至首剂后第4年。
主要发现
- 第1至4年,接种组233例、安慰剂组228例发生至少一次住院VCD(RR=0.511,95%CI 0.42-0.62)。
- 住院VCD中,接种组48例、安慰剂组47例被归类为临床重症。
- ≥9岁儿童中,接种组(n=17 629)88例、安慰剂组(n=8 821)136例发生至少一次住院VCD(RR=0.324,95%CI 0.24-0.43)。
- <9岁儿童第1至4年总体RR=0.786(95%CI 0.60-1.03),6-8岁儿童保护效果高于2-5岁儿童。
- 接种组<9岁儿童(尤其2-5岁)第3年住院VCD病例多于对照组,但第4年未增多。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Our objective was to describe the risk of hospital admission for virologically confirmed dengue (VCD) and the risk of clinically severe hospitalized VCD occurring up to 4 years after the first dose (years 1 to 4) in three randomized clinical trials comparing tetravalent dengue vaccine with placebo. METHODS: The relative risks (RR) for hospitalized VCD from first dose to year 4 were estimated by year and age-group in individual and combined studies. RESULTS: Overall, from Year 1 to Year 4, 233 and 228 participants had at least one episode of hospitalized VCD in the vaccinated (n = 22 603) and placebo (n = 11 301) groups, respectively (RR = 0.511, 95% CI 0.42-0.62). Among these, 48 and 47 cases, respectively, were classified as clinically severe. In children aged ≥9 years, 88 and 136 participants had at least one episode of hospitalized VCD in the vaccinated (n = 17 629) and placebo (n = 8821) groups, respectively (RR = 0.324; 95% CI 0.24-0.43). In vaccinated participants aged <9 years, particularly in those aged 2-5 years, there were more hospitalized VCD cases compared with the control participants in Year 3 but not in Year 4. The overall RR in those aged <9 years for Year 1 to Year 4 was 0.786 (95% CI 0.60-1.03), with a higher protective effect in the 6-8 year olds than in the 2-5 year olds. CONCLUSIONS: The overall benefit-risk remained positive in those aged ≥9 years up to year 4, although the protective effect was lower in years 3 and 4 than in years 1 and 2.
引用
- Arredondo-García JL, Hadinegoro SR, Reynales H, et al. Four-year safety follow-up of the tetravalent dengue vaccine efficacy randomized controlled trials in Asia and Latin America. Clin Microbiol Infect. 2018. PMID: 29408333. doi:10.1016/j.cmi.2018.01.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。